Osel Devices Ltd. (OSELDEVICE)
SME CapPharma stocks · SME cap · NSE
Osel Devices Ltd. is an Indian electronics and medtech manufacturer, incorporated in 2006. It operates in LED displays, hearing aids, and Philips-branded mobile devices, covering design-to-delivery with in-house R&D and manufacturing in Greater Noida. It aims to be a brand-building, retail-capable, globally competitive platform.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is acceptable, price trend argues for patience, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Average · 30/100YoY data unavailable — classification deferred
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹146 Cr | NDF | +47.5% |
| EBITDA | ₹29 Cr | +45.0% | +16.0% |
| Operating margin | 20.0% | +0 bps | +300 bps |
| PAT | ₹14 Cr | NDF | +16.7% |
| PAT margin | 9.6% | -253 bps | -61 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
OSELDEVICE reported strong FY26 consolidated financial performance with revenue from operations up 56.9% YoY to ₹292.7 Cr, EBITDA up 59.7% YoY to ₹53.3 Cr (18.2% margin), and PAT up 45.7% YoY to ₹29.2 Cr (10.0% margin).
The company demonstrated robust growth across its multi-vertical business in FY26, driven by strategic forward integration in hearing aids, expansion in mobile, and recurring revenue initiatives in LED. Key certifications and planned capacity additions position it for continued growth, particularly in export markets, despite significant working capital build-up.
Revenue by vertical
Latest issuer-disclosed distribution across 3 reported categories.
Forward Integration in Hearing Aids
Scaling SFL clinics to capture the full hearing-health value chain, moving from government supply to higher-margin private/clinic channels.
Mobile at Volume
Deepening the Philips portfolio with smartphones (commercialized Mar 2026) and planned tablets (Dec 2026), and growing nationwide distribution reach.
LED & Recurring SaaS
Expanding enterprise installs and scaling the proprietary CMS subscriber base, which generates recurring, hardware-agnostic revenue (300+ locations live).
JNPA SEZ Hub
Developing an export-grade manufacturing and EMS base at India's busiest port, commercializing from April 2027, for higher volumes and wider product range.
JNPA SEZ Manufacturing Hub
A strategic, export-ready manufacturing hub with far greater installed capacity and wider product range, with commercialization from April 2027.
Global Ageing Population
Ageing populations are expanding the addressable base for hearing aids worldwide, with 700M+ people projected to have disabling hearing loss by 2050.
Underserved Indian Hearing Aid Market
India has 91M+ people with hearing loss but <3% treatment rate, representing a significant headroom for growth.
Growth in LED Display Market
The global LED display market is projected to reach $26.98B by 2031, with Asia-Pacific driving ~47-49% of global consumption and India's market growing rapidly.
India's Smartphone Market Opportunity
India is the world's second-largest smartphone market, projected to reach 277M units by 2033, with an open middle segment for trusted international brands.
Audiologist Shortage in India
A severe shortage of audiologists (1:500,000 ratio vs. 1:10,000 global best practice) restricts market access for many players, though OSEL aims to mitigate this via vertical integration.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The investor presentation provides full financial year (FY26 vs FY25) and half-year (H2 FY26 vs H2 FY25) comparisons, indicating that annual and half-yearly performance trends are the primary focus for assessing growth and profitability.
Domestic Formulations Growth (Hearing Aids)
India's hearing aid market is $235M (2024) with <3% treatment rate, indicating significant headroom. OSEL addresses affordability, access, awareness, and distribution through its full-stack platform.
US/Export Growth
FY26 exports were ~₹23 Cr. The USFDA registered facility is key to accessing the world's largest hearing-aid market. JNPA SEZ is export-oriented, targeting international customers and global brands from April 2027.
Launch Pipeline (Mobile)
Smartphones under the Philips brand were commercialized in March 2026. Tablets are planned for launch in December 2026 to deepen the portfolio.
Approvals & Certifications
USFDA registered facility, MD-5 CDSCO, ISO 13485, ZED Gold, BIS (Visual Display Units & Hearing Aids), and ISO 9001 are in place, providing a strong regulatory moat.
Vision for Integrated Electronics Group
Management's vision is to become an integrated, forward-looking electronics group, focusing on brand-building, retail capability, and global competitiveness.
Reinforcing Pillars of Growth
The growth strategy involves reinforcing pillars such as forward integration, mobile volume, LED recurring SaaS, JNPA SEZ hub, OEM supply, and certified exports.
Capturing Full Value Chain
The company aims to capture the full value chain from manufacturing to audiologist consultation, fitting, and aftercare through SFL Hearing Solutions.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| SFL Hearing Clinics | ~40 clinics operating today | Pan-India clinic-network expansion targeted |
| LED CMS Locations | 300+ locations live today | Target of 1 Lakh+ locations for recurring revenue |
| JNPA SEZ Commercialization | LOI received for proposed business | Commercialization from April 2027 |
| Philips Mobile Portfolio Expansion | Feature Phones (2025), Smartphones (Mar 2026) | Tablets launch expected Dec 2026 |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
39Bearishfull bear SMA stack · SMA20 -9.3% / mo · MACD + · near 52W low · sector +2.2pp vs Nifty (3M)
Technical chart
OSELDEVICEdaily · 1Y · AUTO-22.9%Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 46.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~10.2% over last month) — short-term momentum negative.
- RSI(14) at 46 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 54% off 52W high · 8% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 57 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 57 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Fair-value margin of safety is positive at 48.2%.
- Growth contributes 20/25 to the score.
- Quality contributes 13/20 to the score.
Main drags
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
- Valuation is weaker at 13/30; verify the latest quarterly trend.
- Balance sheet is weaker at 7/15; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +1 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 36th percentile within Pharma. Main check: cash conversion is weak at 28/100.
Healthy Trust Lite: Promoter holding is 64.8%. Key concern: Promoter holding fell 6.7%.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 36th pctile, median 70 · SME: 60th pctile, median 64
6 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 64.8%.
- ▸Promoter pledge is zero.
- ▸ROCE is 23.4%.
- ▸OPM spread across recent quarters is 5%.
Trust risks
- ▸Promoter holding fell 6.7%.
- ▸Operating cash flow is negative at ₹-23 Cr.
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 23.50
- P/B
- 3.35
- EV/EBITDA
- 14.44
- Market Cap
- 685.00Cr
Profitability
- ROE
- 18.70%
- ROCE
- 23.40%
- ROA
- 8.12%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 57.53%
- EPS 5Y
- 45.00%
- Revenue 3Y
- 57.53%
- EPS 3Y
- 45.00%
Balance Sheet
- Debt/Equity
- 0.47
- Interest Coverage
- 5.30×
- Altman Z
- 4.93
- Book Value
- 115.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -23.00 Cr
- EPS TTM
- 16.51
Shareholding
- Promoter Hold
- 64.84%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 6%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.